Brought to you by 
Yamanouchi gets Japanese & Korean rights to Cygnus Dx
29 Mar 2001
Executive Summary
Yamanouchi licensed exclusive Japanese and Korean marketing rights to Cygnus's (drug delivery and diagnostic products) GlucoWatch, for which Cygnus could receive upfront fees and milestones of $10mm, plus royalties.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Yamanouchi gets Japanese & Korean rights to Cygnus Dx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice